The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Prothena Corporation (“Prothena” or the “Company”) (NASDAQGS: PRTA) violated federal securities laws.
On October 15, 2015, Prothena announced its late-stage Phase 2b “PRONTO” study and expansion of its Phase 1/2 clinical trial for the antibody NEOD001. On April 23, 2018, Prothena announced it was ending development of NEOD001 after its Phase 2b PRONTO trial failed to reach either its primary or secondary endpoints. Following this news, shares of Prothena fell from a close of $36.84 on April 20, 2018, to a close of $11.50 per share on April 23, 2018.
To receive more information, please fill out the form.